Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that "buying high and selling higher" is the way to make far more money in lesser time.Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ahead of their future growth potential. In such a situation, invest ...

Paul Bradbury/OJO Images via Getty Images Investment Overview This is my third note for Seeking Alpha covering Amneal Pharmaceuticals (NASDAQ:AMRX), the "global pharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines, including retail generics, injectables, biosimilars and specialty branded pharmaceuticals", according to its 2023 annual report / 10K submission. In March 2022, I gave Amneal stock a "Buy" recommendation after its share price ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 93-4225266 (State or other jurisdiction ...

Q1 2024 Earnings Call May 3, 2024 Cautionary Statement on Forward Looking Statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expe ...

Financial Data and Key Metrics Changes - Q1 2024 total net revenue reached $659 million, an 18% increase year-over-year [6][22] - Adjusted EBITDA for Q1 was $152 million, reflecting a 31% growth [6][23] - Adjusted EPS for Q1 was $0.14, up 17% compared to the previous year [24] Business Line Data and Key Metrics Changes - Generics segment net revenue was $391 million, growing 14% driven by a diverse portfolio [22] - Specialty segment net revenues reached $105 million, a 15% increase, supported by the launch of ONGENTYS [22] - AvKARE segment net revenues grew by 33% to $163 million, reflecting strong growth across all customer channels [23] Market Data and Key Metrics Changes - The company fills approximately 175 million prescriptions annually in the U.S., with a focus on complex generics and injectables [7] - The biosimilars market is expected to see significant growth, with an estimated $192 billion in annual branded biologics losing exclusivity from 2024 to 2028 [11] Company Strategy and Development Direction - The strategic vision is to be a global, diversified pharmaceutical company providing access to high-quality, affordable medicines [6] - The company is expanding its portfolio in biosimilars and injectables, with plans to launch over 30 new products in 2024 [10][11] - International expansion is a focus, with expectations to add $5.2 billion in revenues by 2027 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving financial commitments for 2024 and beyond, citing strong execution and growth momentum [6][24] - The recent approval of naloxone is seen as a significant step in addressing the opioid crisis, with plans to expand access through various channels [8][25] - The company is targeting the higher end of its full-year revenue outlook, expecting total net revenue of $2.55 billion to $2.65 billion [25] Other Important Information - The company has resolved legacy legal matters, including a nationwide opioid settlement, which is expected to alleviate financial overhangs [25] - The company has built capacity to supply up to 10 million units of naloxone starting next year [30] Q&A Session Summary Question: Can you talk about the California contract for naloxone? - The California contract starts now, with potential purchases of up to 3.2 million units per year, ramping up demand over time [28] Question: What is the earnings cadence for this year? - The company is focused on maximizing performance while also investing in R&D for long-term growth [33][34] Question: Can you provide an update on ONGENTYS and PEMRYDI? - Positive feedback has been received for ONGENTYS, and PEMRYDI is expected to drive growth as a ready-to-use oncology therapy [36][38] Question: What are the dynamics driving sales for ALYMSYS? - Strong sales are attributed to a well-established commercial team and a broader product portfolio that enhances negotiating power [49] Question: What is the potential for biosimilars Prolia and XGEVA? - Launches are expected in 2026, with good market penetration anticipated due to established relationships [62]

Exhibit 99.1 AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS ‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle on a nationwide opioids settlement, payable over ten years ‒ ‒ Af irming 2024 Full Year Guidance ‒ BRIDGEWATER, NJ, May 3, 2024 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") announced its results today f ...

Company Overview - Amneal Pharmaceuticals (AMRX) shares increased by 12% to close at $6.05, following a notable trading volume that exceeded typical levels [1] - The stock had previously experienced a 7.7% decline over the past four weeks [1] Product Launch - Amneal announced the commercial launch of over-the-counter Naloxone Hydrochloride Nasal Spray, 4mg, in the U.S. after receiving FDA approval [1] - This product serves as a generic equivalent to Emergent BioSolutions' Narcan HCI Nasal Spray, providing an affordable option for treating opioid overdoses [1] Financial Expectations - The company is projected to report quarterly earnings of $0.09 per share, reflecting a year-over-year decrease of 25% [2] - Expected revenues are $621.86 million, which is an 11.5% increase compared to the same quarter last year [2] Earnings Estimate Trends - The consensus EPS estimate for Amneal has remained unchanged over the last 30 days, indicating a lack of upward revisions that typically correlate with stock price increases [2] - Monitoring Amneal's stock is advised to determine if the recent price jump can lead to sustained strength [2] Industry Context - Amneal is part of the Zacks Medical - Drugs industry, where Verrica Pharmaceuticals Inc. (VRCA) also operates [3] - VRCA's stock decreased by 0.9% to $6.79, but it has seen a 28.8% return over the past month [3] - Verrica's consensus EPS estimate has remained unchanged at -$0.54, representing a significant year-over-year decline of 315.4% [3]

Amneal Pharmaceuticals (AMRX) shares rallied 7.3% in the last trading session to close at $6.34. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 0.2% gain over the past four weeks.The rise in share price is attributable to positive investor expectations for the company’s prospects. Amneal is involved in the development, marketing, and distribution of a diverse portfolio of over 270 pharmaceutical products, in ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ Commission file number 001-38485 Amneal Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware (State or oth ...

Amneal Pharmaceuticals, Inc. AMRX) Q4 2023 Earnings Conference Call March 1, 2024 8:30 AM ET Company Participants Chirag Patel - Co-Founder & Co-CEO Chintu Patel - Co-Founder & Co-CEO Tasos Konidaris - CFO Andy Boyer - Generics Joe Renda - SVP & CCO, Specialty Harsher Singh - SVP, Biosciences Jason Daly - Chief Legal Officer Tony DiMeo - IR Conference Call Participants Nathan Rich - Goldman Sachs David Amsellem - Piper Sandler Balaji Prasad - Barclays Chris Schott - J.P. Morgan Leszek Sulewski - Truist Secu ...